Ionis Pharmaceuticals

IONS · NASDAQ

$45.40+$1.02 (+2.30%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $44.38

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Employees: 1,402
Headquarters: Carlsbad, California
Listed: May 17, 1991
Sector: Health Care
Industry: Biotechnology
Website: ionis.com

Leadership

Ionis Pharmaceuticals executives
Name	Title	Since	Age
Joseph Loscalzo	—	—	73
Brett Monia	—	2009	63
Elizabeth Hougen	—	—	63
Shannon Devers	—	—	54
C. Frank Bennett	—	—	68
Patrick O'Neil	—	—	51
Joseph Baroldi	—	—	47
Brian Birchler	—	—	47
Richard Geary	—	—	67
Kyle Jenne	—	—	49
Holly Kordasiewicz	—	—	—
Eugene Schneider	—	2013	52
Eric Swayze	—	—	58
Joseph Wender	—	—	80
B. Lynne Parshall	—	1991	70
Spencer Berthelsen	—	—	72
Allene Diaz	—	—	60
Michael Hayden	—	—	73
Joan Herman	—	—	71
Joseph Klein	—	—	63
Michael Yang	—	—	63

Revenue by product and region

Fiscal year ended Dec 31, 2025: $943.71M total revenue

By product

Research and Development Revenue [Member]$507.86M53.8%
Collaborative Agreement Revenue [Member]$465.79M49.4%
Commercial Revenue [Member]$435.85M46.2%
Royalty$285.53M30.3%
Product$115.31M12.2%
Other$77.08M8.2%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Ionis Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Novartis NOVN.SW	Supplier and customer	CH	0.67
Bayer BAYN.DE	Supplier and customer	DE	0.45
AstraZeneca AZN.L	Supplier and customer	GB	0.39
Biogen BIIB	Supplier and customer	US	0.38
Regulus Therapeutics RGLS	Supplier and customer	US	0.37
PTC Therapeutics PTCT	Supplier and customer	US	0.33
Alnylam Pharmaceuticals ALNY	Supplier and customer	US	0.09
Achaogen, Inc. AKAOQ	Supplier and customer	US	0.07
GlaxoSmithKline GSK.L	Supplier and customer	GB	0.04
Bellevue Group BBN.SW	Supplier and customer	CH	-0.02

Similar companies

Companies in the same industry as Ionis Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.